Sophiris Bio Inc (NASDAQ:SPHS) was up 8.5% during trading on Tuesday . The stock traded as high as $2.15 and last traded at $2.05. Approximately 1,004,200 shares were traded during mid-day trading, an increase of 258% from the average daily volume of 280,653 shares. The stock had previously closed at $1.89.

Several equities research analysts recently commented on SPHS shares. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Sophiris Bio in a research report on Friday, September 15th. Maxim Group set a $6.00 price objective on shares of Sophiris Bio and gave the stock a “buy” rating in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Sophiris Bio currently has a consensus rating of “Buy” and a consensus target price of $6.25.

The company has a debt-to-equity ratio of 0.60, a current ratio of 13.37 and a quick ratio of 13.37.

A hedge fund recently bought a new stake in Sophiris Bio stock. Mesirow Financial Investment Management Inc. bought a new stake in Sophiris Bio Inc (NASDAQ:SPHS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned approximately 0.18% of Sophiris Bio at the end of the most recent quarter. 5.56% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Sophiris Bio (SPHS) Trading Up 8.5%” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/12/14/sophiris-bio-sphs-trading-up-8-5.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.